Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses.
Patients that are immunosuppressed might be at risk of serious influenza-associated complications. As a result, multiple guidelines recommend influenza vaccination for patients infected with HIV, who have received solid-organ transplants, who have received haemopoietic stem-cell transplants, and patients on haemodialysis. However, immunosuppression might also limit vaccine responses. To better inform policy, we reviewed the published work relevant to incidence, outcomes, and prevention of influenza infection in these patients, and in patients being treated chemotherapy and with systemic corticosteroids. Available data suggest that most immunosuppressed populations are indeed at higher risk of influenza-associated complications, have a general trend toward impaired humoral vaccine responses (although these data are mixed), and can be safely vaccinated--although longitudinal data are largely lacking. Randomised clinical trial data were limited to one study of HIV-infected patients with high vaccine efficacy. Better trial data would inform vaccination recommendations on the basis of efficacy and cost in these at-risk populations.
Kunisaki
Ken M
KM
Pulmonary Section, Minneapolis Veterans Affairs Medical Center, Minneapolis, MN 55417, USA. kunis001@umn.edu
Janoff
Edward N
EN
D000998:Antiviral Agents / Q000627:therapeutic use*; D006801:Humans; D016867:Immunocompromised Host; D007252:Influenza Vaccines / Q000009:adverse effects / Q000276:immunology*; D007251:Influenza, Human / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology / Q000401:mortality*
D000998:Antiviral Agents; D007252:Influenza Vaccines